TriArm Therapeutics develops a non-viral CAR-T cell therapy platform that enhances manufacturing efficiency and reduces costs, enabling broader access to curative treatments for cancer patients. The company addresses the limitations of traditional CAR-T therapies, which often exclude patients due to high costs and complex manufacturing processes.
Funding
Funding not disclosed
Founders
Product
Problem
Current CAR-T cell therapies face limitations in manufacturing efficiency and high costs, restricting patient access to these potentially curative treatments, particularly in regions outside the US. Complex manufacturing processes and scalability challenges further hinder the widespread adoption of CAR-T therapies.
Solution
TriArm Therapeutics is developing a non-viral CAR-T cell therapy platform designed to overcome the manufacturing and cost barriers associated with traditional CAR-T approaches. Their FIT™ (Fast-In-Time) platform enables rapid vein-to-vein turnaround, enhanced yield, and improved stemness at a reduced cost. By leveraging investigator-initiated trials (IITs) in regions with limited CAR-T access, TriArm aims to expedite clinical validation and de-risk costly US clinical trials, ultimately delivering more accessible and affordable CAR-T products to a broader patient population. The platform incorporates Enhancive Technologies such as FlexTune™, CD30+ FineTune™, and CD3ε FlowTune™ to improve polyclonality, persistence, safety, and cytokine release profiles.
Target Audience
The primary target audience includes cancer patients who are marginalized by the high costs and manufacturing constraints of conventional CAR-T therapies, as well as clinicians and researchers seeking more efficient and accessible CAR-T solutions.
Features
- FIT™ (Fast-In-Time) non-viral manufacturing process for rapid CAR-T cell production
- FlexTune™ adaptors (OppoTAGs) to optimize CAR-T activity timing, potency, and diversity
- CD30+ FineTune™ technology to amplify CAR-T expansion while preventing fratricide and promoting stem-like cell characteristics
- CD3ε FlowTune™ modulator for a gentler cytokine release profile and enhanced therapeutic index
- Streamlined clinical translation process utilizing investigator-initiated trials (IITs) in ex-US regions